Varda Space Industries
Microgravity-enabled life-sciences company operating W-Series free-flying orbital platforms that process pharmaceutical active ingredients and materials in orbit and return product to Earth. Also serves as a hypersonic testbed for reentry and orbital flight testing.
FINANCIAL HEALTH
SECTOR POSITION
RECENT COVERAGE
| Date | Source | Headline |
|---|---|---|
| May 21, 2026 | SpaceNews | Sixth Varda mission successfully returns |
| May 13, 2026 | Ars Technica — Space | Could this be the moment that drug manufacturing takes off in orbit? |
REGISTRY DATA
Source: space_company_registry.json · Operator homepage → · Corporate homepage (El Segundo, CA HQ; 2026 copyright) documents Varda's microgravity-enabled life-sciences platform and W-Series reentry missions through W-6, establishing operator status in the phar
METHODOLOGY
Launch history and subsystem outcomes aggregate from AstraVeris's launch_events table with Wilson 95% lower bounds on success rates. ARI scores come from the 11-factor composite (/finance/methodology/). Constellation counts derive from the live CelesTrak/GCAT object catalog. Gov contracts from USAspending.gov awards; private deals from deduplicated pipeline deal extraction. Absence of a row means "not tracked" — we never fabricate. See /methodology/ for the full data model and /data-licensing/ for licensing terms.
Not investment advice. For insurance underwriting, verify against primary-source filings and operator investigation reports.